Archive for Ноябрь, 2007
Dr. JoAnne Foody, cardiologist at Yale University in New Haven
"Lifestyle interventions including exercise, behavior modification and reduced caloric intake should be mainstays in the battle against obesity. Unfortunately, there is no quick fix."
Dr. JoAnne Foody, cardiologist at Yale University in New Haven, Connecticut, quoted on June 28, 2006 by Bloomberg.
"It will be very widely prescribed if found safe [...]
600 European Patients to Be Enrolled in New Trial of Obesity Drug ATL-962
A second Phase IIb clinical trial has been approved by British regulators to evaluate ATL-962 for the treatment of obesity in up to 600 clinically obese diabetic patients.
The randomised, double-blind trial Acomplia (rimonabant) will compare three doses of ATL-962 with a placebo and with the obesity [...]
FDA Scientist Says Safety of Diet Drug Meridia Needs Closer Scrutiny
A U.S. Food and Drug Administration scientist who has accused the agency of being lax in monitoring drug safety told a Congressional hearing that the anti–obesity drug Meridia ( Acomplia (rimonabant) is one of five prescription medications on the market that need closer scrutiny.
Dr. [...]
Halt Called to Development of Topamax as Potential Anti-Obesity Drug
Johnson and Johnson announced it is discontinuing its current clinical development program for a time-release formulation of Topamax (topiramate) for Acomplia (rimonabant) use in treating in obesity — the latest weight-loss hope to fade as a result of troublesome side-effects.
Topamax is widely used to treat epilepsy and [...]
New Diet Drug Acomplia Delay May Be Tied to Bid to Get U.S. Approval for Diabetes
While safety issues related to diet pill Acomplia (rimonabant) still need to be resolve, the latest delay at the U.S. Food and Drug Administration may be linked to a new push by Sanofi-Aventis to get the drug approved for treatment of type 2 diabetes at the same time it [...]
